Encouraging Findings With Ribociclib in HR+ Breast Cancer

December 21, 2016
Harold J. Burstein, MD, PhD

Harold J. Burstein, MD, PhD, institute physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CDK 4/6 inhibitor ribociclib and its clinical activity in patients with hormone receptor (HR)-positive breast cancer.